Annabelle Monnet
Roche (Switzerland) · 32 works · 2,722 citations · h-index 11
Top works
- Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries
- The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: Estimates of Radiation-Related Cancer Risks
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
- Trial of Prasinezumab in Early-Stage Parkinson’s Disease
- Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
- MIRROS: A Randomized, Placebo-Controlled, Phase III Trial of Cytarabine ± Idasanutlin in Relapsed or Refractory Acute Myeloid Leukemia
- Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
- Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
- Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials
- Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab
- Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study
- A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data
- Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III
- MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.
- Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion—With an application to the design of a clinical trial in acute myeloid leukemia
- Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
- Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials
- Estimating the meaningful within-patient change threshold for the MDS-UPDRS Part III (P1-1.Virtual)
- Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study
- Exploratory Analysis of PASADENA Open-label Extension Evaluating the Effect of Prasinezumab on the Progression of Motor Signs and Symptoms (S30.006)